COVID-19 vaccine effectiveness
(Randomized evidence)
Methods
Latest news:Last search date July 30, 2023. No further screening is planned after this date. Extraction is ongoing for all pending studies.
A list of studies pending extraction is available here.
meta-COVID
Perform your own analysis using COVID-NMA data for prime vaccination (last search date 14/12/2022), create and download your forest plots by clicking below:
Vaccine types
COVID-19 BOOSTER DOSE VACCINATION: updated daily
Vaccine efficacy, immunogenicity and safety of booster vs no booster (tables)
Vaccine efficacy, immunogenicity and safety of booster VS booster (tables)
COVID-19 PRIME VACCINATION: Last search date December 14, 2022.
Vaccine efficacy and safety for vaccine vs placebo / no vaccine (forest plots)
Vaccine efficacy and safety for vaccine vs vaccine (forest plots)
Vaccine efficacy, immunogenicity and safety of heterologous vs homologous vaccination (tables)
Vaccine efficacy and safety against variants of concern (forest plots)
Search studies
| Trial | Type | Comparisons | Design | Participants | Sample size | Overall risk of bias Highest assessment |
Full description | |
|---|---|---|---|---|---|---|---|---|
| Intervention 1 | Intervention 2 | |||||||
|
NCT05293548 National Vaccine and Serum Institute, China, Beijing Zhong Sheng Heng Pharmaceutical Technology, Lanzhou Institute of Biological Products; Sinopharm-Beijing Al Kaabi N, Signal Transduct Ther, 2023 Full text Commentary Commentary |
Protein subunit |
BBIBP-CorV/Boost NVSI-06-09 |
BBIBP-CorV/Boost BBIBP-CorV |
RCTPhase 2 | Healthy adults previously vaccinated with two or three doses of BBIBP-CorV at least 6 months prior to enrollment at a single center in United Arab Emirates | N= 516 |
Some concerns Details |
|
|
NCT04672395 Clover Biopharmaceuticals Inc./Dynavax Bravo L, Lancet, 2022 Full text Commentary Commentary |
Protein subunit |
SCB-2019 30 mcg + CpG/Alum |
Placebo |
RCTPhase 2-3 | Healthy adults or with stable chronic conditions, both SARS-CoV-2 seropositive and seronegative, at 31 centers in Belgium, Brazil, Colombia, Philippines, and South Africa. | N= 30174 |
Some concerns Details |
|
|
ChiCTR2100051998 Sinovac Research and Development Co. Ltd.; Anhui Zhifei Longcom Biopharmaceutical + Institute of Microbiology, Chinese Academy of Sciences Cao Y, Cell Res, 2021 Full text Commentary |
Inactivated virus |
CoronaVac/Boost ZF2001 |
CoronaVac/Boost CoronaVac |
RCTPhase 2 | Healthcare professionals with no previous confirmed COVID-19 at a single center in China who had received two doses of CoronaVac in a 28-day interval 4–8 months earlier | N= 164 |
Some concerns Details |
|
|
NCT04495933 The University of Queensland; Syneos Health; CSIRO Manufacturing; Seqirus; Coalition for Epidemic Preparedness Innovations Chappell K, Lancet, 2021 Full text Commentary |
Protein subunit |
2 doses 5-mcg SARS-CoV-2 Sclamp 2 doses 15-mcg SARS-CoV-2 Sclamp 2 doses 45-mcg SARS-CoV-2 Sclamp 1 dose 45-mcg SARS-CoV-2 Sclamp, 1 dose placebo |
0·9% saline (0·5 mL) |
RCTPhase 1 | Healthy SARS-CoV-2 infection-free adults aged 18-55 at one center in Australia. | N= 120 |
Some concerns Details |
|
|
NCT05087368 Clover Biopharmaceuticals Inc./Dynavax ; AstraZeneca + University of Oxford Costa Clemens, Open Forum Infect. Dis., 2022 Full text Commentary Commentary Commentary Commentary |
Protein subunit |
ChAdOx1-S/Boost 9 mcg SCB-2019 + alum ChAdOx1-S/Boost 9 mcg SCB-2019 + CpG + alum ChAdOx1-S/Boost 30 mcg SCB-2019 + CpG + alum |
ChadOx1/Boost ChadOx1 |
RCTPhase 2 | Adults including healthy or stable co-morbidities with no history of SARS-CoV-2 infection who had previously received 2 doses of ChAdOx1-S1-S vaccine 6 months (±4 weeks) before enrollment in 3 centers in Brazil | N= 120 |
Some concerns Details |
|
|
NCT04646590 Anhui Zhifei Longcom Biopharmaceutical Dai L, N Engl J Med, 2022 Full text Commentary Commentary |
Protein subunit |
ZF2001 |
Placebo |
RCTPhase 3 | Adults 18 years of age or older with no history of Covid-19, positive tests for SARS-CoV-2 exposure or vaccination, or of congenital or acquired immune deficiency or autoimmune disease at 32 clinical centers across Uzbekistan, Indonesia, Pakistan, Ecuador and China. | N= 28904 |
Some concerns Details |
|
|
NCT04611802 Novavax Dunkle L M, N Engl J Med, 2021 Full text Commentary |
Protein subunit |
NVX-CoV2373 |
Placebo |
RCTPhase 3 | Healthy adults in 113 sites in the USA and 6 in Mexico | N= 29949 |
Some concerns Details |
|
|
NCT05197153 AstraZeneca+University of Oxford; Moderna TX; Medigen Vaccine Biologics+Dynavax+NIAID Estephan L, Vaccine, 2023 c Full text Commentary |
Protein subunit |
mRNA-1273/Boost MVC-COV1901 mRNA-1273/Boost ChAdOx1 mRNA-1273/Boost 1/2 MVC-COV1901 |
mRNA-1273/Boost 1/2 mRNA-1273 |
RCTPhase 2 | Adults who received ChAdOx1, mRNA-1273, or MVC-COV1901 as prime vaccination with no history of COVID-19 , in 4 centers in Taiwan | N= 163 |
Some concerns Details |
|
|
NCT05197153 AstraZeneca+University of Oxford; Moderna TX; Medigen Vaccine Biologics+Dynavax+NIAID Estephan L, Vaccine, 2023 a Full text Commentary |
Protein subunit |
MVC-COV1901/Boost 1/2 MVC-COV1901 MVC-COV1901/Boost mRNA-127 MVC-COV1901/Boost ChAdOx1 |
MVC-COV1901/Boost MVC-COV1901 |
RCTPhase 2 | Adults who received ChAdOx1, mRNA-1273, or MVC-COV1901 as prime vaccination with no history of COVID-19 , in 4 centers in Taiwan | N= 313 |
Some concerns Details |
|
|
NCT05197153 AstraZeneca+University of Oxford; Moderna TX; Medigen Vaccine Biologics+Dynavax+NIAID Estephan L, Vaccine, 2023 b Full text Commentary |
Protein subunit |
ChadOx1/boost MVC-COV1901 ChadOx1/boostmRNA-1273 (half dose) |
ChadOx1/boostChadOx1 |
RCTPhase 2 | Adults who received ChAdOx1, mRNA-1273, or MVC-COV1901 as prime vaccination with no history of COVID-19 , in 4 centers in Taiwan | N= 323 |
Some concerns Details |
|
|
NCT04368988 Novavax Formica N, PLoS Med, 2021 Full text Commentary |
Protein subunit |
NVX-CoV2373 5mcg D0/21 NVX-CoV2373 5mcg D0/Placebo D21 NVX-CoV2373 25mcg D0/21 NVX-CoV2373 25mcg D0/Placebo D21 |
Placebo D0/D21 |
RCTPhase 2 | Healthy adults (stable comorbidities permitted) aged 18-84 years at 17 centers in Australia and USA | N= 1288 |
Some concerns Details |
|
|
NCT04537208 Sanofi Pasteur, GlaxoSmithKline Goepfert P, Lancet, 2021 Full text Commentary |
Protein subunit |
CoV2 preS dTM 1.3 mcg + AFO3 D0/21 CoV2 preS dTM 1.3 mcg + ASO3 D0/21 CoV2 preS dTM 2.6 mcg + AFO3 D0/21 CoV2 preS dTM 2.6 mcg + ASO3 D0/21 CoV2 preS dTM 2.6 mcg D0/21 |
Placebo D0/21 |
RCTPhase 1-2 | Health adults aged 18 years and older and SARS-CoV-2 infection-free in 10 centres in the USA. | N= 441 |
Some concerns Details |
|
|
NCT05585567 Livzon Pharmaceutical Group Inc He Q, J. Clin. Med., 2022 b Full text Commentary |
Protein subunit |
Any inactivated COVID-19 vaccine/Boost inactivated COVID-19 vaccine/Boost BV-01-B5 |
Any inactivated COVID-19 vaccine/Boost inactivated COVID-19 vaccine/Boost BV-01-B5 |
RCTPhase 1 | Healthy adults, aged 18 -59 years old, with no previous COVID-19 infection that had received three doses of ICV (CoronaVac) in one center in China | N= 36 |
Some concerns Details |
|
|
NCT05583357 Livzon Pharmaceutical Group Inc He Q, J. Clin. Med., 2022 a Full text Commentary |
Protein subunit |
Any inactivated COVID-19 vaccine/Boost inactivated COVID-19 vaccine/Boost V-01D-351 |
Any inactivated COVID-19 vaccine/Boost inactivated COVID-19 vaccine/Boost CoronaVac |
RCTPhase 1 | Healthy adults with no history of SARS-CoV-2 infection and 3 doses of CoronaVac or BBIBP-CorV in one centre in China | N= 20 |
Some concerns Details |
|
|
NCT04583995; EudraCT 2020-004123-16 Novavax Heath P, Clin Infect Dis, 2022 Full text Commentary |
Protein subunit |
NVX-CoV2373 5 mcg D0/21 |
Placebo D0/21 |
RCTPhase 3 | Adults 18 to 84 years old who were healthy or had stable chronic medical conditions with no history of COVID-19 at 33 centres in the UK. | N= 15,185 |
Some concerns Details |
|
|
RPCEC00000346 Center for Genetic Engineering and Biotechnology (CIGB) Hernandez-Bernal, EClinicalMedicine, 2022 a ABDALA Full text Full text Commentary |
Protein subunit |
25mcg CIGB D0/D14/D28 25mcg CIGB D0/D28/D56 50mcg CIGB D0/D28/D56 50mcg CIGB D0/D14/D28 |
Placebo |
RCTPhase 1 | Healthy adults that were SARS-CoV-2 infection-free and with no recent contact or high-risk of exposure to COVID-19 at a single center in Cuba | N= 132 |
Some concerns Details |
|
|
RPCEC00000346 Center for Genetic Engineering and Biotechnology (CIGB) Hernandez-Bernal , EClinicalMedicine, 2022 b ABDALA Full text Full text Commentary |
Protein subunit |
25mcg CIGB D0/D14/D28 50mcg CIGB D0/D14/D28 |
Adjuvant |
RCTPhase 2 | Adults 19 to 80 years old that were SARS-CoV-2 infection-free and with no recent contact or high-risk of exposure to COVID-19 at a single center in Cuba | N= 726 |
Some concerns Details |
|
|
RPCEC00000359 Center for Genetic Engineering and Biotechnology (CIGB) Hernandez-Bernal F, SSRN, 2022 Abdala-3 Full text Commentary Commentary Commentary |
Protein subunit |
Abdala |
Placebo |
RCTPhase 3 | Adults, healthy or with controlled co-morbidities and no history of SARS-CoV-2 at 18 centers in Cuba | N= 48290 |
Some concerns Details |
|
|
NCT04695652 Medigen Vaccine Biologics+Dynavax+NIAID Hsieh SM, Lancet, 2021 Full text Commentary |
Protein subunit |
MVC-COV1901 |
Placebo |
RCTPhase 2 | Healthy adults and adults with stable pre-existing medical conditions at 11 centers in Taiwan. | N= 3854 |
Some concerns Details |
|
|
NCT04368988 Novavax Keech C, N Engl J Med, 2020 Full text Commentary |
Protein subunit |
NVX-CoV2373 25mcg D0/21 NVX-CoV2373 5mcg/Matrix-M1 50 mcg D0/21 NVX-CoV2373 25mcg/Matrix-M1 50 mcg D0/21 NVX-CoV2373 25mcg/Matrix-M1 50 mcg D0/ Placebo D21 |
Placebo D0/21 |
RCTPhase 1 | Healthy adult volunteers, SARS-CoV-2 infection-free and no history of SARS-CoV-2 infection in two centres in Australia. | N= 134 |
Some concerns Details |
|
|
ChiCTR2100045108 Guangdong Provincial Center for Disease Control and Prevention Liao Y, Emerg Microbes Infec, 2021 Full text Commentary |
Protein subunit |
V-01 10 mcg V-01 25 mcg V-01 50 mcg |
Placebo |
RCTPhase 1 | Healthy seronegative adults with no history of COVID-19 in a single center in China | N= 180 |
Some concerns Details |
|
|
NCT04951388 Medigen Vaccine Biologics+Dynavax+NIAID Liu LTC, medRxiv, 2022 Full text Commentary Commentary |
Protein subunit |
MVC-COV1901 15 mcg D0/28 |
Placebo |
RCTPhase 2 | Adolescents aged 12 to 17 years with no serious medical conditions and no previous SARS-CoV-1 infection or vaccination at 5 centers in Taiwan. | N= 399 |
Some concerns Details |
|
|
NCT04533399; PACTR202009726132275 Novavax Madhi S, Lancet HIV, 2022 Full text Commentary |
Protein subunit |
5mcg NVX-CoV2373 with 50 mcg Matrix-M1 adjuvant |
Placebo |
RCTPhase 2 | HIV-negative adults (18 to 84 years) and medically stable HIV-positive adults (18 to 64 years) at 16 sites in South Africa | N= 4419 |
Some concerns Details |
|
|
NCT04368988 Novavax Mallory R, Lancet Infect Dis, 2022 Full text Full text Commentary Commentary |
Protein subunit |
NVX-CoV2373/Boost NVX-CoV2373 |
NVX-CoV2373/Boost placebo |
RCTPhase 2 | Healthy adults (stable comorbidities and confirmed COVID-19 with mild symptoms permitted) who had received 2 doses NVX-CoV2373 or placebo in a trial at 17 centers in Australia and USA | N= 383 | N/A | |
|
NCT04712110 Novavax Masuda T, Vaccine, 2022 b Full text Commentary Commentary Commentary |
Protein subunit |
NVX-CoV2373 |
Placebo |
RCTPhase 1-2 | Healthy Japanese adults aged ≥ 20 years with no history/risk of SARS-CoV-2 infection and no prior exposure to other approved/investigational SARS-CoV-2 vaccines or treatments at 2 centers in Japan. | N= 200 |
Some concerns Details |
|
|
NCT04640402 West China Hospital of Sichuan University Meng F, Signal Transduct Tar, 2021 b Full text Commentary |
Protein subunit |
COVID-19 vaccine (Sf9 cells) 20 mcg D0/14/28 COVID-19 vaccine (Sf9 cells) 40 mcg D0/21 COVID-19 vaccine (Sf9 cells) 20 mcg D0/21 COVID-19 vaccine (Sf9 cells) 40 mcg D0/14/28 |
Placebo |
RCTPhase 2 | Healthy adults with no history of COVID-19 in a single centre in China | N= 960 |
Some concerns Details |
|
|
NCT04530656 West China Hospital of Sichuan University Meng F, Signal Transduct Tar, 2021 a Full text Commentary |
Protein subunit |
COVID-19 vaccine (Sf9 cells) 20 mcg D0/28 COVID-19 vaccine (Sf9 cells) 40 mcg D0/28 COVID-19 vaccine (Sf9 cells) 40 mcg D0/14/28 |
Placebo |
RCTPhase 1 | Healthy adults with no history of COVID-19 in a single centre in China | N= 168 |
Some concerns Details |
|
|
NCT04683484 Nanogen Pharmaceutical Biotechnology JSC Nguyen T, Lancet, 2022 a Full text Commentary |
Protein subunit |
Nanocovax 25 mcg |
Nanocovax 25 mcg |
RCTPhase 1 | Healthy HIV-negative and seronegative adults at a single center in Vietnam | N= 60 |
Some concerns Details |
|
|
NCT04683484 Nanogen Pharmaceutical Biotechnology JSC. Nguyen T, Lancet, 2022 b Full text Full text Full text Commentary |
Protein subunit |
Nanocovax 25 mcg |
Adjuvant |
RCTPhase 2 | Healthy HIV-negative and seronegative adults at 2 centers in Vietnam | N= 560 |
Some concerns Details |
|
|
NCT04922788 Nanogen Pharmaceutical Biotechnology JSC. Nguyen TP, medRxiv, 2022 Full text Commentary Commentary |
Protein subunit |
Nanocovax |
Placebo |
RCTPhase 3 | Healthy adult without previous or current SARS-CoV-2 infection in four centres in Vietnam. | N= 13007 |
Details |
|
|
RPCEC00000338 Finlay Vaccine Institute Pérez-Rodríguez S, Vaccine, 2022 Full text Commentary |
Protein subunit |
FINLAY-FR-1A 25 mcg FINLAY-FR-1A 50 mcg |
FINLAY-FR-1 |
RCTPhase 1 | Adults, age 19-59, with no history of previous SARS-CoV-2 infection at a single center in Cuba. | N= 60 |
Low Details |
|
|
NCT04405908 Clover Biopharmaceuticals Inc./Dynavax Richmond P, Lancet, 2021 Full text Commentary |
Protein subunit |
SCB-2019 3 mcg SCB-2019 3 mcg + AS03 18-75yrs D1/D22 SCB-2019 3 mcg + CpG/Alum 18-75yrs D1/D22 SCB-2019 9 mcg SCB-2019 9 mcg + AS03 18-75yrs D1/D22 SCB-2019 9 mcg + CpG/Alum 18-75yrs D1/D22 SCB-2019 30 mcg SCB-2019 30 mcg + AS03 18-75yrs D1/D22 SCB-2019 30 mcg + CpG/Alum 18-75yrs D1/D22 |
0.5mL 0.9% sodium chloride placebo |
RCTPhase 1 | Healthy SARS-CoV-2 serology/DNA negative adults aged 18-75 years at one study center in Australia | N= 151 |
Low Details |
|
|
NCT04527575 EpiVac LLC; VECTOR Ryzhikov AB, Infektsiia Immun, 2021 Full text Commentary |
Protein subunit |
EpiVacCorona |
Placebo |
RCTPhase 2 | Healthy adult SARS-CoV-2 infection-free volunteers in a single center in Russia. | N= 86 |
Some concerns Details |
|
|
jRCT2031210470 Shionogi;Pfizer/BioNTech+Fosun Pharma Shinkai M, Vaccine, 2022 Full text Full text Commentary Commentary |
Protein subunit |
BNT162b2/Boost S-268019-b |
BNT162b2/Boost BNT162b2 |
RCTPhase 2-3 | Adults who had received 2 doses of BNT162b2 vaccine at least 6 months earlier with no history of SARS-CoV-2 infection at a single centre in Japan | N= 204 |
Some concerns Details |
|
|
ChiCTR2100045107 Institute of Biophysics, Chinese Academy of Sciences; Livzon Bio Inc.; Guangdong Provincial Centre for Disease Control and Prevention; Gaozhou Center for Disease Control and Prevention Shu Y-J, Chin. Med. J., 2021 Full text Commentary |
Protein subunit |
V-01 10 mcg V-01 25 mcg V-01 50 mcg |
Placebo |
RCTPhase 2 | Younger (18-59) and older (60+) healthy adults with no current or past SARS-CoV-2 infection (PCR and ELISA) at a single centre in China | N= 880 |
Some concerns Details |
|
|
NCT04762680 Sanofi Pasteur+GlaxoSmithKline Sridhar S, Lancet Infect Dis , 2022 Full text Commentary |
Protein subunit |
CoV2 preS dTM 15 mcg CoV2 preS dTM 10 mcg |
CoV2 preS dTM 5 mcg |
RCTPhase 2 | Adults with and without prior SARS-CoV-2 infection and risk factors for severe disease at 20 centers in the USA and Honduras | N= 722 |
Some concerns Details |
|
|
ISRCTN27841311; EudraCT 2021-001275-16 Pfizer BioNTech + Fosun Pharma / Novavax / Moderna + NIAID Stuart A, Lancet, 2021 b Com-COV2 Full text Commentary Commentary |
Protein subunit |
1 dose BNT162b2 followed by 1 dose NVX-CoV2373 1 dose BNT162b2 followed by 1 dose mRNA-1273 |
2 doses BNT162b2 |
RCTPhase 2 | Adults over 50 years previously vaccinated with one dose of BNT162b2 at 9 centres in the UK | N= 532 |
Some concerns Details |
|
|
ISRCTN27841311; EudraCT 2021-001275-16 AstraZeneca + University of Oxford / Novavax / Moderna + NIAID Stuart A, Lancet, 2021 a Com-COV2 Full text Commentary Commentary |
Protein subunit |
1 dose ChAdOx1 followed by 1 dose NVX-CoV2373 1 dose ChAdOx1 followed by 1 dose mRNA-1273 |
2 doses ChAdOx1 |
RCTPhase 2 | Healthy adults over 50 years previously vaccinated with one dose of ChAdOx1 nCoV-19 in 9 centres in the UK | N= 540 |
Some concerns Details |
|
|
IRCT20150303021315N24 ; NCT05005559 Vaxine/CinnaGen Tabarsi P, Clin Microbiol Infect, 2022 Full text Commentary |
Protein subunit |
SpikoGen 2 doses 25mcg D0/21 |
Placebo |
RCTPhase 3 | Immunocompetent adults with stable medical conditions at a single center in Iran. | N= 16876 |
Some concerns Details |
|
|
IRCT20150303021315N23 ; NCT04944368 Vaxine/CinnaGen Tabarsi P, CMI, 2022 Full text Commentary |
Protein subunit |
SpikoGen 2 doses 25mcg D0/21 |
Placebo |
RCTPhase 2 | Healthy adults or those with stable medical conditions, with or without prior COVID-19 infection, at a single center in Iran. | N= 400 |
Some concerns Details |
|
|
CTRI/2021/08/036074 Biological E;AstraZeneca+University of Oxford Thuluva , medRxiv, 2022 b Full text Commentary Commentary |
Protein subunit |
2 IM doses of 25 mcg BECOV2 |
ChAdOx1 |
RCTPhase 3 | Healthy adults without a history of Covid-19 vaccination or SARS-CoV-2 infection at 20 centers in India. | N= 2140 |
Some concerns Details |
|
|
CTRI/2021/10/037066 Biological E. Limited Thuluva S, Vaccine, 2022 a Full text Full text Commentary Commentary Commentary |
Protein subunit |
BECOV2<12 to ≥5 BECOV2<18 to ≥12 |
Placebo |
RCTPhase 2-3 | Healthy children and adolescents who were SARS-CoV-2 RT-PCR and anti-SARS-CoV-2 antibody negative in 23 centers in India | N= 624 |
Low Details |
|
|
CTRI/2022/01/039366 Biological E Limited Thuluva S, medRxiv, 2023 b Full text Commentary |
Protein subunit |
BBV152/Boost BECOV2 |
BBV152/Boost Placebo |
RCTPhase 3 | Adults including elderly and co-morbidities in 7 centres in India. | N= 208 |
Low Details |
|
|
RPCEC00000347 Instituto Finlay de Vacunas Toledo-Romani ME, Med, 2022 Full text Commentary Commentary Commentary |
Protein subunit |
FINLAY-FR-2-25 mcg +FR-1-50 mcg |
Adjuvant |
RCTPhase 2b | Healthy adults with no known or suspected history of COVID-19 at 2 centers in Cuba. | N= 810 |
Some concerns Details |
|
|
RPCEC00000354 Instituto Finlay de Vacunas Toledo-Romani ME, medRxiv, 2022 b Full text Full text Commentary |
Protein subunit |
FINLAY-FR-2-25 mcg +FR-1-50 mcg |
Placebo |
RCTPhase 3 | Adults in medically stable condition with no self-reported previous COVID-19 infection at 48 centers in Cuba | N= 44031 |
Some concerns Details |
|
|
RPCEC00000354 Instituto Finlay de Vacunas Toledo-Romani ME, medRxiv, 2022 a Full text Full text Commentary |
Protein subunit |
FINLAY-FR-2-25 mcg, 2 doses |
Placebo |
RCTPhase 3 | Adults in medically stable condition with no self-reported previous COVID-19 infection at 48 centers in Cuba | N= 44031 |
Some concerns Details |
|
|
NCT05011526 Medigen; AstraZeneca + University of Oxford Torales J, Vaccine, 2022 Full text Full text Commentary Commentary |
Protein subunit |
MVC-COV1901 15 mcg D0/28 |
ChAdOx1 |
RCTPhase 3 | Healthy adults or adults with pre-existing medical conditions who are in stable condition and with no known SARS-CoV-2 infection in the 3 months prior at 2 centers in Paraguay. | N= 1030 |
Some concerns Details |
|
|
NCT05096832 Livzon Pharmaceutical Wang X-Y, Emerg Microbes Infec, 2022 Full text Full text Commentary Commentary |
Protein subunit |
BBIBP-CorV or CoronaVac/Boost V-01 |
BBIBP-CorV or CoronaVac/Boost placebo |
RCTPhase 3 | Healthy adults or those with stable chronic conditions, with no previous history of COVID-19, at 15 centers in Pakistan and Malaysia. | N= 10,241 |
Some concerns Details |
|
|
NCT04445194 Anhui Zhifei Longcom Biopharmaceutical Yang S, Lancet, 2021 a Full text Commentary |
Protein subunit |
ZF2001 25 mcg per 0.5 mL, with aluminum hydroxide adjuvant, days 0, 30, 60 |
aluminum hydroxide adjuvant, days 0, 30, 60 |
RCTPhase 1 | Healthy SARS-CoV-2 infection-free adults aged 18-59 at 2 centers in China | N= 50 |
Some concerns Details |
|
|
NCT04466085 Anhui Zhifei Longcom Biopharmaceutical Yang S, Lancet, 2021 b Full text Commentary |
Protein subunit |
ZF2001 25 mcg per 0.5 mL, with aluminum hydroxide adjuvant, days 0, 30, 60 |
aluminum hydroxide adjuvant, days 0, 30 |
RCTPhase 2 | Healthy SARS-CoV-2 infection-free adults aged 18-59 at 1 center in China | N= 900 |
Low Details |
|
|
ChiCTR2200057758 Walvax Biotech Co., Ltd ; Walvax Biotechnology + Shanghai RNACure Biopharma ; Shanghai Zerun Biotechnology + Walvax Biotechnology + CEPI ; Sinovac Research an Zhang Y, Nature, 2023 Full text Full text Commentary |
Non replicating viral vector |
CoronaVac/Boost ChAdTS-S CoronaVac/Boost RQ3013 CoronaVac/Boost ZR202-CoV CoronaVac/Boost CoronaVac |
CoronaVac/Boost placebo |
RCTPhase 2 | Adults aged 18-59, healthy or with stable pre-existing disease and with no history of SARS-CoV-2 infection, at a single center in China. | N= 250 |
Some concerns Details |
|